A study from the Division of Molecular Diabetes Research, Department of Diabetes and Metabolic Diseases, City of Hope National Medical Center, Duarte, California, USA shows that “MicroRNA-26a regulates insulin sensitivity and metabolism of glucose and lipids.” This study was published in the 11 May 2015 issue of the Journal “Journal of Clinical Investigation” (one of the best journal in Clinical Medicine with an impact factor of 13.675) by Prof Huang F, Fu X, and others.
On the foundation of this interesting finding, Dr L Boominathan PhD, Director-cum-chief Scientist of GBMD, reports that: Insight into Metformin’s mechanism of action: Metformin, the widely used drug in the treatment of T2DM, inhibits obesity-induced insulin resistance, glucose tolerance and lipid accumation via up regulation of its target gene MiRNA-26a.
Significance:
Given that: (1) more than 387 million people worldwide are affected by Diabetes mellitus (DM); (2) Obesity is one of the main cause for the development of T2DM; (3) the life-long drug treatment required to treat DM; and (4) the global economic cost spent for diabetes treatment in 2014 was little more than 600 billion US dollars, there is an urgent need to find a way to increase insulin sensitivity in obese individuals.
This study suggests, for the first time, that Metformin, by increasing the expression of its target gene MiRNA-26a, it may prevent/decrease: (1) obesity-induced insulin resistance; (2) glucose tolerance; and (3) Plasma triglycerides and cholesterol levels. Thus, pharmacological formulations encompassing “Metformin or its analogues” may be used to prevent obesity-induced insulin resistance.
Idea Proposed/Formulated by: Dr L Boominathan Ph.D.
Web: http://genomediscovery.org
Terms & Conditions apply http://genomediscovery.org/registration/terms-and-conditions/
To cite: Boominathan, Insight into Metformin’s mechanism of action: Metformin, the widely used drug in the treatment of T2DM, inhibits obesity-induced insulin resistance, glucose tolerance and lipid accumation via up regulation of its target gene MiRNA-26a, 10/June/2015, 10.03 am, Genome-2-Bio-Medicine Discovery center (GBMD), http://genomediscovery.org
Courtesy: When you cite drop us a line at info@genomediscovery.org
* Research cooperation